Rapamycin for Longevity: The Complete Guide

Overview

Rapamycin is a naturally occurring macrolide compound first isolated from a soil bacterium (Streptomyces hygroscopicus) collected on Easter Island (Rapa Nui) in 1972. It was initially developed as an antifungal agent, then found to have potent immunosuppressive properties. The FDA approved sirolimus (brand name Rapamune) for preventing organ transplant rejection, and it has since been approved for lymphangioleiomyomatosis (LAM), a rare lung disease.

The longevity research community's interest in rapamycin stems from its ability to inhibit the mechanistic target of rapamycin (mTOR), a highly conserved nutrient-sensing kinase that regulates cell growth, proliferation, autophagy, and metabolism. mTOR integrates signals from nutrients, growth factors, and energy status to determine whether cells should grow and divide or conserve resources and repair. Inhibiting mTOR with rapamycin shifts cells toward a maintenance and repair state — mimicking aspects of caloric restriction, the most robust intervention for lifespan extension across species (Harrison et al., 2009).

Rapamycin extended lifespan in every organism tested: yeast, worms, flies, and mice. The landmark 2009 study by the NIA Interventions Testing Program (ITP) demonstrated that rapamycin increased median lifespan in genetically heterogeneous mice by 9% in males and 14% in females, even when treatment began at 20 months of age — the equivalent of approximately 60 human years (Harrison et al., 2009). This finding was unprecedented: no other pharmacological intervention had so robustly extended lifespan in a rigorous, multi-site mammalian study.

Since then, research has expanded into human applications. Mannick et al. demonstrated that low-dose rapamycin analogs improved immune function in elderly volunteers, enhancing their response to influenza vaccination (Mannick et al., 2014; Mannick et al., 2018). The Dog Aging Project is testing rapamycin in companion dogs to bridge the gap between mouse studies and human longevity trials. A growing number of longevity-focused physicians prescribe rapamycin off-label at low intermittent doses.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The mTOR Pathway

The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that forms two distinct protein complexes: mTORC1 and mTORC2. These complexes serve as central integrators of cellular nutrient sensing and growth signaling (Laplante & Sabatini, 2012).

• mTORC1 promotes protein synthesis, lipid synthesis, and cell growth when nutrients and growth factors are abundant. It suppresses autophagy (the cellular recycling process). Rapamycin directly and potently inhibits mTORC1.
• mTORC2 regulates cytoskeletal organization, cell survival, and insulin signaling. Rapamycin does not directly inhibit mTORC2, though prolonged or high-dose exposure can disrupt mTORC2 assembly in some cell types — a distinction relevant to side effect profiles.

When nutrients are abundant, mTORC1 drives cellular growth and proliferation. When nutrients are scarce (as in caloric restriction or fasting), mTORC1 activity decreases, and cells shift toward autophagy, stress resistance, and repair. Rapamycin pharmacologically mimics this nutrient-scarce signal, activating repair pathways without requiring actual caloric restriction.

Autophagy Activation

One of the most important downstream effects of mTORC1 inhibition is the activation of autophagy — the process by which cells degrade and recycle damaged organelles, misfolded proteins, and other cellular debris. Autophagy declines with age, and its decline is associated with the accumulation of cellular damage that drives aging and age-related disease. Rapamycin restores autophagy toward youthful levels in aged tissues (Laplante & Sabatini, 2012).

Senescent Cell Reduction

Cellular senescence — the permanent arrest of cell division in damaged cells — contributes to age-related tissue dysfunction through the senescence-associated secretory phenotype (SASP), a pro-inflammatory cocktail of cytokines and proteases. Rapamycin has been shown to reduce the SASP and decrease senescent cell accumulation in preclinical models, contributing to reduced tissue inflammation and improved organ function with aging (Laberge et al., 2015).

Immune Modulation

At high continuous doses (as used in transplant medicine), rapamycin is immunosuppressive — it prevents T-cell activation and proliferation. At low intermittent doses used in longevity protocols, the effect appears qualitatively different: rather than broadly suppressing immunity, it improves immune function in aged individuals. Mannick et al. demonstrated that mTOR inhibition enhanced the response of elderly volunteers to influenza vaccination, suggesting that low-dose rapamycin rejuvenates rather than suppresses aged immune function (Mannick et al., 2014).

Mitochondrial Function

mTORC1 inhibition promotes mitochondrial quality control through mitophagy (selective autophagy of damaged mitochondria) and enhances mitochondrial biogenesis. Aged tissues accumulate dysfunctional mitochondria that produce excessive reactive oxygen species (ROS). Rapamycin improves mitochondrial membrane potential and reduces ROS production in aged cells (Laplante & Sabatini, 2012).

Caloric Restriction Mimicry

Caloric restriction (CR) is the most consistently replicated intervention for extending lifespan across species. CR reduces mTOR signaling, activates autophagy, improves insulin sensitivity, and reduces inflammation — the same pathways modulated by rapamycin. This mechanistic overlap has led to rapamycin's characterization as a "caloric restriction mimetic," achieving many of the molecular effects of CR without reducing food intake (Harrison et al., 2009).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Harrison 2009: The Landmark ITP Study

The NIA Interventions Testing Program (ITP) is a multi-site, rigorous testing platform for candidate longevity interventions in genetically heterogeneous mice. In 2009, Harrison et al. reported that rapamycin extended median lifespan by 9% in males and 14% in females, with treatment beginning at 20 months of age — the equivalent of roughly 60 years in humans (Harrison et al., 2009).

Key aspects of this study:

• Conducted at three independent sites (Jackson Laboratory, University of Michigan, University of Texas Health Science Center)
• Used genetically heterogeneous mice (UM-HET3), reducing the risk of strain-specific artifacts
• Treatment started late in life, demonstrating that lifespan extension does not require lifelong treatment
• Rapamycin was delivered in food (encapsulated in an enteric coating) at 14 ppm
• Maximum lifespan was also extended, not just median — suggesting a fundamental slowing of aging rather than prevention of a single disease

Subsequent ITP studies confirmed and extended these findings, showing dose-dependent effects and lifespan extension when treatment was started at younger ages (Miller et al., 2014).

Mannick 2014 & 2018: Human Immune Aging

Joan Mannick and colleagues conducted two pivotal human studies examining the effects of mTOR inhibition on immune aging:

• Mannick et al. (2014): A randomized, placebo-controlled trial in elderly volunteers (≥65 years) showed that 6 weeks of low-dose everolimus (a rapamycin analog) improved the response to influenza vaccination by approximately 20%. The treatment was well-tolerated with minimal side effects at the lowest dose tested (Mannick et al., 2014).
• Mannick et al. (2018): A follow-up Phase 2a trial tested a combination of mTOR inhibitors (BEZ235/everolimus) in elderly volunteers. Treatment reduced infection rates by approximately 40% in the year following the 6-week treatment course, and upregulated antiviral gene expression. Importantly, the beneficial effects persisted months after discontinuation (Mannick et al., 2018).

These studies provided the first direct evidence that mTOR inhibition can improve age-related immune decline in humans at doses and schedules that are well-tolerated.

Bitto 2016: Transient Treatment

Bitto et al. demonstrated that a brief course of rapamycin (3 months of treatment beginning at 20 months of age) was sufficient to extend lifespan in mice. This finding is significant because it suggests that continuous lifelong treatment may not be necessary — even transient mTOR inhibition can produce lasting benefits. The study also showed improvements in multiple organ systems including the heart, liver, and gut (Bitto et al., 2016).

The Dog Aging Project

The Dog Aging Project (DAP) is a large-scale longitudinal study of aging in companion dogs. A key component is the Test of Rapamycin in Aging Dogs (TRIAD), a randomized, placebo-controlled clinical trial testing low-dose rapamycin in middle-aged large-breed dogs. Preliminary results from earlier pilot studies showed improved cardiac function in treated dogs, with echocardiographic evidence of enhanced diastolic function (Urfer et al., 2017).

The DAP represents a critical translational step between mouse studies and human longevity trials. Dogs share the human environment, develop similar age-related diseases, and age on a timescale (8–15 years) that makes longitudinal studies feasible.

Additional Preclinical Findings

Limitations of Current Research

• No human lifespan trials: No randomized controlled trial has tested whether rapamycin extends human lifespan. Such a trial would require decades and tens of thousands of participants.
• Mouse-to-human translation: While mouse lifespan data is robust, interventions that extend mouse lifespan do not always produce equivalent effects in humans.
• Dose and schedule uncertainty: The optimal dose and frequency for human longevity use has not been established through clinical trials.
• Long-term safety at low doses: Most human safety data comes from transplant patients using high continuous doses. Long-term safety at intermittent low doses used for longevity is not well characterized.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indications

Off-Label Longevity Use

A growing number of physicians prescribe rapamycin off-label for longevity and age-related disease prevention. This practice is based on the preclinical lifespan extension data, the Mannick human immune aging studies, and clinical experience. Off-label prescribing is legal when a licensed physician determines it is medically appropriate for an individual patient.

Common rationales reported by prescribing clinicians include:

• Slowing biological aging as measured by biomarkers (epigenetic clocks, inflammatory markers)
• Improving age-related immune decline (immunosenescence)
• Reducing age-related inflammatory signaling
• Supporting cardiovascular health through reduced cardiac hypertrophy and improved vascular function
• Activating autophagy for cellular maintenance
• Potential neuroprotective effects

Rapalogs (Rapamycin Analogs)

Several rapamycin analogs (rapalogs) have been developed with modified pharmacokinetic properties:

Among rapalogs, everolimus has the most longevity-relevant human data due to the Mannick trials. However, most longevity clinicians prescribe generic sirolimus (rapamycin) due to cost, availability, and the direct preclinical lifespan data.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Longevity Dosing Protocols

Dosing protocols above are derived from published research, clinician reports, and the longevity medicine literature — not from FDA-approved labeling for longevity use. Key references: Mannick et al., 2014 · Bitto et al., 2016 · Harrison et al., 2009

Why Weekly (Intermittent) Dosing?

The rationale for intermittent rather than daily dosing is based on the differential sensitivity of mTORC1 and mTORC2 to rapamycin:

• mTORC1 is directly and acutely inhibited by rapamycin. Even intermittent exposure produces robust mTORC1 inhibition, activating autophagy and repair pathways.
• mTORC2 is not directly bound by rapamycin but can be disrupted by chronic continuous exposure. mTORC2 disruption is associated with insulin resistance and metabolic side effects.
• Weekly dosing allows rapamycin levels to fall below the threshold for mTORC2 disruption between doses (given the ~62-hour half-life), while still providing sufficient mTORC1 inhibition.

Transplant vs. Longevity Dosing Comparison

Sources: FDA — Rapamune (sirolimus) prescribing information · Mannick et al., 2014 — mTOR inhibition dosing in elderly · Bitto et al., 2016 — Transient rapamycin treatment

Lab Monitoring

Clinicians prescribing rapamycin for longevity typically monitor:

• Lipid panel: Rapamycin can elevate total cholesterol, LDL, and triglycerides. Baseline and periodic monitoring recommended.
• Complete blood count (CBC): To monitor for cytopenias (low blood cell counts), which are rare at longevity doses.
• Fasting glucose and HbA1c: To monitor for insulin resistance or glucose elevation.
• Comprehensive metabolic panel: Liver and kidney function.
• Rapamycin trough level: Some clinicians check a trough level (drawn just before the next weekly dose) to confirm adequate clearance between doses.

Timing and Administration

• Rapamycin is taken orally as a tablet (Rapamune) or compounded capsule
• High-fat meals increase absorption; some clinicians recommend taking with or without food consistently
• Grapefruit juice significantly increases rapamycin blood levels (inhibits CYP3A4 metabolism) — some clinicians use this intentionally, others advise avoidance
• Many longevity users take their weekly dose on the same day each week

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Users Report

Reported Biomarker Changes

Subjective Reports

• Skin quality: Improved skin texture, reduced fine wrinkles, and enhanced wound healing are among the most frequently reported subjective benefits. Preclinical data supports rapamycin's effects on skin aging (Chung et al., 2019).
• Immune resilience: Reduced frequency of colds and respiratory infections is commonly reported, consistent with the Mannick trial findings.
• Exercise recovery: Some users report faster recovery from exercise, potentially related to enhanced autophagy and reduced inflammation.
• Energy and cognition: Subjective improvements in mental clarity and energy, though these are difficult to attribute specifically to rapamycin.
• Mouth sores: The most common negative report — aphthous-like ulcers that typically resolve with dose reduction or treatment breaks.

Dog Aging Project Preliminary Observations

Early pilot data from the Dog Aging Project showed that dogs receiving low-dose rapamycin demonstrated improved cardiac function on echocardiography. Owners reported subjective improvements in activity level and vitality, though placebo-controlled data from the full TRIAD trial is pending (Urfer et al., 2017).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Side Effects at Longevity Doses

Transplant-Dose Side Effects (Not Typical at Longevity Doses)

At continuous daily transplant doses (2–5 mg/day with trough levels 4–12 ng/mL), rapamycin causes a range of side effects that are generally not observed or are significantly mitigated at intermittent longevity doses:

• Significant immunosuppression with increased infection risk
• Impaired wound healing
• Proteinuria
• Interstitial pneumonitis
• Lymphedema
• Significant insulin resistance
• Pronounced dyslipidemia requiring treatment

The distinction between continuous high-dose and intermittent low-dose effects is central to the rationale for longevity dosing protocols. The side effect profiles differ substantially.

Mouth Sore Management

Mouth sores are the most clinically relevant side effect at longevity doses. Management strategies reported by clinicians include:

• Dose reduction (e.g., from 5 mg to 3 mg weekly)
• Skipping a dose and restarting at a lower dose
• Switching from weekly to biweekly dosing
• Dexamethasone oral solution (0.5 mg/5 mL) used as a swish-and-spit mouthwash
• Avoiding acidic, spicy, or rough-textured foods during episodes

Drug Interactions

Rapamycin is metabolized by the CYP3A4 enzyme and is a substrate of P-glycoprotein. Significant interactions include:

• CYP3A4 inhibitors (ketoconazole, erythromycin, clarithromycin, grapefruit juice): Increase rapamycin levels significantly
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort): Decrease rapamycin levels
• Cyclosporine: Increases rapamycin levels (relevant in transplant settings)
• Live vaccines: Should be avoided due to immunosuppressive potential

Contraindications

• Active infection: Immunosuppressive effects may impair infection clearance
• Pregnancy and breastfeeding: Teratogenic potential; contraindicated
• Hypersensitivity: Known allergy to sirolimus or any component
• Severe hepatic impairment: Reduced metabolism may lead to toxic levels
• Pre-planned surgery: Many clinicians recommend holding rapamycin 1–2 weeks before elective surgery due to wound healing concerns

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval History

Off-Label Prescribing

Off-label prescribing — using an FDA-approved drug for an indication not specified in its approved labeling — is legal and common in medical practice. The FDA regulates drug approval and marketing, but does not regulate the practice of medicine. A licensed physician may prescribe any FDA-approved drug for any condition they judge medically appropriate for their patient.

Rapamycin for longevity falls under this framework. It is prescribed by longevity-focused physicians, functional medicine practitioners, and some primary care physicians who have incorporated aging biology into their practice. No special license or approval is required beyond a standard medical license and prescriptive authority.

Access Pathways

• Standard pharmacy with prescription: Generic sirolimus tablets (0.5 mg, 1 mg, 2 mg) are available at retail pharmacies with a valid prescription. Insurance coverage varies — most plans cover it for approved indications but may not cover it when prescribed for longevity.
• Compounding pharmacies: Some longevity clinicians prescribe compounded rapamycin in custom doses (e.g., 3 mg, 4 mg, 5 mg capsules) for convenience. Compounding pharmacy costs are out-of-pocket.
• Telehealth longevity clinics: Several telehealth platforms specialize in longevity prescribing and offer rapamycin prescriptions with remote physician consultation.

WADA Status

Rapamycin is not specifically listed on the WADA Prohibited List as of the current list. However, athletes should consult with their anti-doping authority, as immunosuppressive agents may fall under certain categories depending on context and sport-specific rules.

International Status

Sirolimus is approved as a prescription drug in most major regulatory jurisdictions (EMA, MHRA, TGA, Health Canada) for transplant and/or LAM indications. Longevity prescribing legality varies by country — off-label prescribing is permitted in most jurisdictions but regulated differently.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Additional Costs

• Physician consultation: Longevity-focused physicians typically charge $200–$500 for an initial consultation and $100–$300 for follow-up visits. Some telehealth platforms offer subscription-based access ($100–$200/month) that includes prescribing and monitoring.
• Lab monitoring: Periodic blood work (lipids, CBC, metabolic panel, fasting glucose) costs $50–$200 per panel if not covered by insurance. Most health insurance covers routine blood work regardless of the reason for ordering.
• Rapamycin blood levels: Trough level testing costs $30–$100 per test. Not always required at longevity doses.

Insurance Coverage

Insurance coverage for rapamycin prescribed for longevity is inconsistent:

• Some insurance plans cover generic sirolimus regardless of indication (the pharmacy system processes the prescription without reviewing the diagnosis)
• Some plans require prior authorization and may deny coverage for off-label longevity use
• Compounded rapamycin is generally not covered by insurance
• Lab work is usually covered under preventive care or routine monitoring benefits

Cost Comparison: Rapamycin vs. Other Longevity Interventions

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Question: Is rapamycin safe for healthy people to take for longevity?

Answer: Rapamycin has a well-characterized safety profile from decades of clinical use in transplant medicine and oncology. At the low intermittent doses used for longevity (1–6 mg weekly), the side effect profile differs substantially from the continuous high-dose transplant setting. The most common side effects at longevity doses are mouth sores and lipid elevation — both manageable with dose adjustment. The Mannick trials demonstrated that low-dose mTOR inhibition was well-tolerated in elderly volunteers (Mannick et al., 2014). However, long-term safety data specific to healthy individuals taking rapamycin at low intermittent doses for longevity does not yet exist.

Question: Does rapamycin suppress the immune system at longevity doses?

Answer: At continuous high doses (transplant dosing), rapamycin is immunosuppressive. At low intermittent doses, the effect appears different. Mannick et al. showed that low-dose mTOR inhibition in elderly volunteers improved immune function rather than suppressing it — enhancing the response to influenza vaccination and reducing infection rates (Mannick et al., 2014; Mannick et al., 2018). The distinction between immunosuppression (continuous high-dose) and immune rejuvenation (intermittent low-dose) is a key concept in rapamycin longevity research. However, individuals with compromised immune systems should exercise additional caution.

Question: Will rapamycin extend human lifespan?

Answer: This has not been demonstrated. Rapamycin extends lifespan in every model organism tested, including mice (9–14% median lifespan extension in the ITP study) (Harrison et al., 2009). However, no human lifespan trial has been conducted or is currently feasible. Such a trial would require decades and enormous sample sizes. The current rationale for human use is based on: (1) robust preclinical lifespan data across species, (2) human data showing improved immune function and reduced infections, (3) mechanistic understanding of mTOR's central role in aging biology. Whether these translate to measurable human lifespan extension remains an open question.

Question: Can I take rapamycin with metformin?

Answer: Some longevity clinicians prescribe rapamycin and metformin together, as they target different aging pathways (mTOR and AMPK, respectively). There is no known direct pharmacokinetic interaction between the two drugs. Metformin may partially counteract rapamycin-induced glucose elevation, which some clinicians view as complementary. However, combination longevity protocols have not been tested in controlled human trials, and the interaction at the biological level is complex — both drugs affect overlapping metabolic pathways.

Question: Should I stop rapamycin before surgery or vaccination?

Answer: Many longevity-focused clinicians recommend holding rapamycin 1–2 weeks before elective surgery due to theoretical wound healing concerns, though this effect is primarily documented at transplant doses. For vaccinations, the Mannick data suggests that low-dose mTOR inhibition may actually enhance vaccine responses in older adults (Mannick et al., 2014). Live vaccines should generally be avoided during rapamycin use. Consult your prescribing physician for guidance specific to your situation.

Question: What is the difference between rapamycin and rapalogs?

Answer: Rapalogs (rapamycin analogs) are chemically modified versions of rapamycin designed to improve specific pharmacokinetic properties. Everolimus (Afinitor) has better oral bioavailability and a shorter half-life (~30 hours vs. ~62 hours for rapamycin). Temsirolimus is administered intravenously. All rapalogs share the same primary mechanism: binding FKBP12 and inhibiting mTORC1. The Mannick immune aging trials used everolimus. Most longevity clinicians prescribe rapamycin (sirolimus) rather than rapalogs due to its lower cost, generic availability, and the direct preclinical lifespan extension data.

Question: Does rapamycin cause diabetes?

Answer: Continuous high-dose rapamycin (as used in transplant medicine) can cause insulin resistance and glucose intolerance, primarily through disruption of mTORC2 signaling. At low intermittent longevity doses, this effect is less common, likely because mTORC2 recovers between weekly doses. Bitto et al. showed that transient rapamycin treatment improved metabolic parameters rather than worsening them (Bitto et al., 2016). Monitoring fasting glucose and HbA1c is standard practice for longevity prescribers. Individuals with pre-existing diabetes or insulin resistance should be monitored closely.

Question: Is rapamycin the same as caloric restriction?

Answer: Rapamycin and caloric restriction share significant mechanistic overlap — both reduce mTORC1 signaling, activate autophagy, improve insulin sensitivity, and reduce inflammation. Rapamycin is characterized as a "caloric restriction mimetic." However, they are not identical. Caloric restriction affects additional pathways (e.g., sirtuins, AMPK activation through energy depletion) that rapamycin does not directly engage. Conversely, rapamycin's pharmacological mTORC1 inhibition is more targeted and consistent than the variable mTOR modulation produced by dietary restriction (Harrison et al., 2009).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Rapamycin (sirolimus) is an FDA-approved mTOR inhibitor with the most robust preclinical evidence for pharmacological lifespan extension in mammals. The NIA Interventions Testing Program demonstrated 9–14% median lifespan extension in genetically heterogeneous mice.
• The mTOR pathway is a central regulator of aging biology. Inhibiting mTORC1 activates autophagy, reduces senescent cell burden, improves mitochondrial function, and shifts cells toward maintenance and repair — overlapping with the mechanisms of caloric restriction.
• Human data is promising but limited. The Mannick trials demonstrated improved immune function and reduced infections in elderly volunteers receiving low-dose mTOR inhibition. No human lifespan trial has been conducted.
• Longevity dosing (1–6 mg weekly) differs substantially from transplant dosing (2–5 mg daily). The intermittent schedule aims to inhibit mTORC1 while allowing mTORC2 recovery, reducing the metabolic side effects seen at transplant doses.
• The most common side effects at longevity doses are mouth sores and lipid elevation — both manageable with dose adjustment. The side effect profile at low intermittent doses differs from the transplant setting.
• Cost is relatively modest at $30–$100/month for generic sirolimus, making it one of the more affordable pharmacological longevity interventions.
• The Dog Aging Project is testing rapamycin in companion dogs, providing a critical translational bridge between mouse and human longevity studies.
• Rapalogs (especially everolimus) share rapamycin's mechanism and have human immune aging data, but most longevity clinicians prescribe generic sirolimus.
• Longevity use is off-label. A growing number of physicians prescribe rapamycin for this purpose, but it is not FDA-approved for longevity or aging prevention.

Questions to Ask a Provider

• Based on my health profile, am I a reasonable candidate for rapamycin?
• What dose and frequency do you recommend, and what evidence supports that protocol?
• What baseline labs should I have before starting, and how often should I monitor?
• How will rapamycin interact with my current medications?
• What side effects should I watch for, and when should I contact you?
• Should I hold rapamycin before planned vaccinations or surgeries?
• How will we assess whether rapamycin is producing measurable benefit?
• What is the plan if I develop mouth sores or lipid changes?

Sources & Further Reading

Landmark Lifespan Studies

• Harrison DE, Strong R, Sharp ZD, et al. (2009) — "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice" — Nature 460:392–395
• Miller RA, Harrison DE, Astle CM, et al. (2014) — "Rapamycin-mediated lifespan increase in mice is dose and sex dependent" — Aging Cell 13:468–477
• Bitto A, Ito TK, Pineda VV, et al. (2016) — "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice" — eLife 5:e16351

Human Clinical Trials

• Mannick JB, Del Giudice G, Lattanzi M, et al. (2014) — "mTOR inhibition improves immune function in the elderly" — Science Translational Medicine 6:268ra179
• Mannick JB, Morris M, Hockey HP, et al. (2018) — "TORC1 inhibition enhances immune function and reduces infections in the elderly" — Science Translational Medicine 10:eaaq1564

mTOR Biology and Mechanisms

• Laplante M, Sabatini DM (2012) — "mTOR signaling in growth control and disease" — Cell 149:274–293
• Laberge RM, Sun Y, Orjalo AV, et al. (2015) — "MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype" — Nature Cell Biology 17:1049–1061

Dog Aging Project

• Urfer SR, Kaeberlein TL, Mailheau S, et al. (2017) — "A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs" — GeroScience 39:117–127

Cardiac and Organ-Specific Effects

• Dai DF, Karunadharma PP, Chiao YA, et al. (2014) — "Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart" — Aging Cell 13:529–539

Cognitive and Neurological Effects

• Spilman P, Podlutskaya N, Hart MJ, et al. (2010) — "Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease" — PLoS ONE 5:e9979

Skin Aging

• Chung CL, Lawrence I, Hoffman M, et al. (2019) — "Topical rapamycin reduces markers of senescence and aging in human skin" — GeroScience 41:861–869

Regulatory and Prescribing Information

• FDA: Rapamune (sirolimus) prescribing information
• GoodRx: Sirolimus pricing information

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.